Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of anlotinib rechallenge in advanced lung cancer
ChiCTR2100047540Phase 2Recruiting
- Sponsor
- Xinxiang Medical University First Affiliated Hospital
- Start
- Jan 1990
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib in bronchial carcinoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), sponsored by Xinxiang Medical University First Affiliated Hospital. Primary endpoint: progression-free survival. Started Jan 1990; status: recruiting.
02
Drugs
anlotinib
03
Conditions
bronchial carcinomasmall cell lung cancer (SCLC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100047540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047540.